• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

每日短时血液透析:415例患者接受1006患者年治疗后的生存情况。

Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years.

作者信息

Kjellstrand Carl M, Buoncristiani Umberto, Ting George, Traeger Jules, Piccoli Giordina B, Sibai-Galland Roula, Young Bessie Ann, Blagg Christopher R

机构信息

Loyola University, Chicago, IL, USA.

出版信息

Nephrol Dial Transplant. 2008 Oct;23(10):3283-9. doi: 10.1093/ndt/gfn210. Epub 2008 May 5.

DOI:10.1093/ndt/gfn210
PMID:18458034
Abstract

BACKGROUND

Survival statistics for daily haemodialysis are lacking as most centres providing this have treated only a small number of patients for short observation times. We pooled our 23-year, 1006-patient-year, five-centre experience of 415 patients treated by short daily haemodialysis.

METHODS

One hundred and fifty patients were treated in-centre, most because of medical complications and 265 by home or self-care haemodialysis. Patients were on daily haemodialysis for 29 +/- 31 (0-272) months. Forty-two percent had primary and 31% had secondary renal failure. Treatment time was 136 +/- 35 min, frequency 5.8 +/- 0.5 times/week and weekly stdKt/V 2.7 +/- 0.55.

RESULTS

Eighty-five patients (20%) died; 5-year cumulative survival was 68 +/- 4.1% and 10-year survival was 42 +/- 9%. Age, secondary renal failure and in-centre dialysis were associated with mortality, while gender, frequency of dialysis (5, 6 or 7 per week), continent, country and blood access were not. Survival was compared with matched patients from the USRDS 2005 Data Report using the standardized mortality ratio and cumulative survival curves. Both comparisons showed that the survival of the daily haemodialysis patients was 2-3 times higher and the predicted 50% survival time 2.3-10.9 years longer than that of the matched US haemodialysis patients. Survival of patients dialyzing daily at home was similar to that of age-matched recipients of deceased donor renal transplants.

CONCLUSIONS

Survival of patients on short daily haemodialysis was 2-3 times better than that of matched three times weekly haemodialysis patients reported by the USRDS.

摘要

背景

由于大多数提供每日血液透析的中心仅治疗了少数患者且观察时间较短,因此缺乏每日血液透析的生存统计数据。我们汇总了我们在23年里、涉及1006患者年、五个中心对415例接受短程每日血液透析治疗患者的经验。

方法

150例患者在中心接受治疗,大多数是由于医疗并发症,265例通过家庭或自我护理血液透析治疗。患者接受每日血液透析29±31(0 - 272)个月。42%为原发性肾衰竭,31%为继发性肾衰竭。治疗时间为136±35分钟,频率为5.8±0.5次/周,每周标准Kt/V为2.7±0.55。

结果

85例患者(20%)死亡;5年累积生存率为68±4.1%,10年生存率为42±9%。年龄、继发性肾衰竭和中心透析与死亡率相关,而性别、透析频率(每周5、6或7次)、大洲、国家和血管通路则无关。使用标准化死亡率比和累积生存曲线将生存率与来自美国肾脏数据系统(USRDS)2005年数据报告中匹配的患者进行比较。两项比较均显示,每日血液透析患者的生存率比匹配的美国血液透析患者高2至3倍,预计50%生存率的时间长2.3至10.9年。在家中进行每日透析的患者生存率与年龄匹配的已故供体肾移植受者相似。

结论

短程每日血液透析患者的生存率比USRDS报告的匹配的每周三次血液透析患者高2至3倍。

相似文献

1
Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years.每日短时血液透析:415例患者接受1006患者年治疗后的生存情况。
Nephrol Dial Transplant. 2008 Oct;23(10):3283-9. doi: 10.1093/ndt/gfn210. Epub 2008 May 5.
2
Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio.使用标准化死亡率比比较短程每日血液透析与传统血液透析之间的生存率。
Hemodial Int. 2006 Oct;10(4):371-4. doi: 10.1111/j.1542-4758.2006.00132.x.
3
Survival with short-daily hemodialysis: association of time, site, and dose of dialysis.短程每日血液透析的生存情况:透析时间、部位和剂量的关联
Hemodial Int. 2010 Oct;14(4):464-70. doi: 10.1111/j.1542-4758.2010.00475.x. Epub 2010 Sep 20.
4
Nightly home hemodialysis: outcome and factors associated with survival.夜间家庭血液透析:结局及与生存相关的因素
Hemodial Int. 2011 Apr;15(2):211-8. doi: 10.1111/j.1542-4758.2011.00542.x. Epub 2011 Mar 21.
5
Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study.每日居家血液透析与匹配腹膜透析患者的死亡率、住院率和技术失败率:一项匹配队列研究。
Am J Kidney Dis. 2016 Jan;67(1):98-110. doi: 10.1053/j.ajkd.2015.07.014. Epub 2015 Aug 28.
6
High-efficiency short daily haemodialysis--morbidity and mortality rate in a long-term study.高效每日短时血液透析——一项长期研究中的发病率和死亡率
Nephrol Dial Transplant. 2006 Aug;21(8):2232-8. doi: 10.1093/ndt/gfl171. Epub 2006 Apr 21.
7
Association between daily haemodialysis, access to renal transplantation and patients' survival in France.法国每日血液透析、肾移植可及性与患者生存率之间的关联。
Nephrology (Carlton). 2018 Mar;23(3):269-278. doi: 10.1111/nep.12974.
8
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.血清成纤维细胞生长因子(FGF)-23水平升高与长期血液透析患者死亡率增加相关。
Nephrol Dial Transplant. 2009 Sep;24(9):2792-6. doi: 10.1093/ndt/gfp191. Epub 2009 Apr 25.
9
[Current peritoneal dialysis compared with haemodialysis: medium-term survival analysis of incident dialysis patients in the Canary Islands in recent years].[近年来加那利群岛新入透析患者的中期生存分析:当前腹膜透析与血液透析的比较]
Nefrologia. 2011;31(2):174-84. doi: 10.3265/Nefrologia.pre2011.Jan.10743.
10
Survival of patients on maintenance haemodialysis over a twenty-year period.维持性血液透析患者二十年的生存率。
Prilozi. 2007 Dec;28(2):99-110.

引用本文的文献

1
Carboxypeptidase B1 in dialyzed chronic kidney disease patients.透析慢性肾病患者中的羧肽酶B1
Sci Rep. 2025 Feb 4;15(1):4254. doi: 10.1038/s41598-025-88332-6.
2
Home versus in-centre haemodialysis for people with kidney failure.居家透析与中心透析治疗肾衰竭患者的效果比较。
Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD009535. doi: 10.1002/14651858.CD009535.pub3.
3
Patient Training and Patient Safety in Home Hemodialysis.家庭血液透析中的患者培训和患者安全。
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1045-1050. doi: 10.2215/CJN.0000000000000416. Epub 2024 Jan 8.
4
Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges.便携式、可穿戴和可植入人工肾系统:需求、机遇和挑战。
Nat Rev Nephrol. 2023 Aug;19(8):481-490. doi: 10.1038/s41581-023-00726-9. Epub 2023 Jun 5.
5
Hidden risks associated with conventional short intermittent hemodialysis: A call for action to mitigate cardiovascular risk and morbidity.传统短期间歇性血液透析相关的潜在风险:呼吁采取行动降低心血管风险和发病率。
World J Nephrol. 2022 Mar 25;11(2):39-57. doi: 10.5527/wjn.v11.i2.39.
6
Paired kidney donation: are we going beyond reasonable limits in living-donor transplantation?配对肾捐献:活体供肾移植是否超越了合理界限?
J Bras Nefrol. 2022 Jul-Sep;44(3):423-427. doi: 10.1590/2175-8239-JBN-2021-0230.
7
Dialysis-Induced Cardiovascular and Multiorgan Morbidity.透析诱导的心血管及多器官疾病
Kidney Int Rep. 2020 Sep 9;5(11):1856-1869. doi: 10.1016/j.ekir.2020.08.031. eCollection 2020 Nov.
8
Home dialysis machine use for emergency dialysis during the COVID-19 pandemic.在新冠疫情期间,家用透析机用于紧急透析。
Clin Kidney J. 2020 Sep 27;13(5):900-902. doi: 10.1093/ckj/sfaa186. eCollection 2020 Oct.
9
Patients' Experiences of Community House Hemodialysis: A Qualitative Study.社区居家血液透析患者的体验:一项定性研究。
Kidney Med. 2019 Sep 24;1(6):338-346. doi: 10.1016/j.xkme.2019.07.010. eCollection 2019 Nov-Dec.
10
Safety and efficacy of the Tablo hemodialysis system for in-center and home hemodialysis.Tablo血液透析系统用于中心血液透析和家庭血液透析的安全性与有效性。
Hemodial Int. 2020 Jan;24(1):22-28. doi: 10.1111/hdi.12795. Epub 2019 Nov 7.